2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - 217-219
Treatment Considerations, Biological Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Immunology, Autoimmune Disorders, Research, Clinical Research, Health Outcomes Research, Study Population, Human, Adult, Pediatric
PAPER

751 Targeting the ERα/HIF-1α metabolic checkpoint: Tofacitinib suppresses macrophage glycolysis and phagocytosis in immune thrombocytopenia during pregnancy

Jie Chen, Qiu-Sha Huang, MD2, Zhuo-Yu An, MD3, Peng Zhao4, Qi Chen5, Hai-Xia Fu, MD6, Jianliu Wang7, Xiaojun Huang, MD,PhD8, Xiaohui Zhang, MD9
1 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
2 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
3 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
4 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
5 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
6 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
7 Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China
8 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
9 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
Background: Immune thrombocytopenia (ITP) during pregnancy poses life-threatening bleeding risks, yet its pathogenesis remains elusive. Estradiol (E2), a critical hormone markedly elevated during pregnancy, impairs megakaryocyte proplatelet formation (Blood, 2025), but its effects on macrophage-mediated platelet phagocytosis are not well understood. Hypoxia-inducible factor-1α (HIF-1α) regulates glycolysis to fuel macrophage phagocytosis. Although we demonstrated its essential role in megakaryocytes (Sci Adv, 2026), elucidating the contribution of HIF-1α to macrophage glycolysis and phagocytosis in ITP during pregnancy is critical for identifying novel therapeutic targets. Notably, Janus kinase (JAK) signaling intersects with HIF-1α regulation. We therefore investigated the mechanism by which E2 regulates macrophage glycolysis and phagocytosis, and the therapeutic potential of the oral JAK inhibitor tofacitinib.
Methods: Serum E2 levels were measured in patients and controls, and correlations with platelet counts were analyzed. Monocyte-derived macrophages were assessed for extracellular acidification, the expression of glycolytic metabolites, and the mRNA/protein expression of glycolytic and cytoskeletal genes. Phagocytosis of macrophages was evaluated by flow cytometry and confocal microscopy following co-culture with pHrodo-labeled platelets. ITP macrophages were exposed to varying concentrations of E2, multiple estrogen receptor (ER) antagonists, HIF-1α knockdown/overexpression agents or tofacitinib to assess glycolysis and phagocytosis. Active pregnant ITP murine models and ITP mice implanted with E2 sustained-release tablets were established to evaluate the impact of E2 and tofacitinib on HIF-1α expression, glycolysis and phagocytosis of macrophages.
Results: Compared with that in healthy controls and ITP patients, serum E2 was significantly elevated in pregnant ITP patients and correlated inversely with platelet count (ρ = -0.755, P = 0.0007). Macrophages derived from these patients displayed markedly enhanced glycolytic activity, as shown by the accelerated extracellular acidification rate (ECAR) and elevated production of lactate and pyruvate (P < 0.05). When cocultured with pHrodo-labeled platelets, these macrophages exhibited a higher proportion of pHrodo+ cells (P < 0.05) as assessed by flow cytometry and confocal microscopy, indicating increased phagocytic capacity.Western blot and qPCR analyses further demonstrated upregulation of glycolytic enzymes (HK2, PKM2 and GLUT1) and the cytoskeletal regulator Rac1 in macrophages from pregnant patients with ITP, accompanied by significantly elevated expression of HIF-1α (P < 0.05).
E2 stimulation was found to dose-dependently induce HIF-1α upregulation in macrophages from ITP patients (P < 0.05), which was effectively inhibited by the ERα antagonist MPP but not by antagonists of ERβ (PHTPP) or GPER (G15). Moreover, high-concentration E2 treatment enhanced the glycolysis and phagocytosis in ITP macrophages, as shown by increased expression of glycolytic enzymes and Rac1, along with elevated ECAR, lactate and pyruvate production, phagocytic index and mean fluorescence intensity (MFI). Both HIF-1α knockdown and tofacitinib treatment significantly reversed the E2-induced upregulation of glycolysis and phagocytosis in macrophages (P < 0.05). Conversely, HIF-1α overexpression effectively reversed tofacitinib-induced metabolic suppression and phagocytic impairment, indicating that tofacitinib exerts its therapeutic effects primarily through the modulation of HIF-1α.
In the murine models, compared with non-pregnant ITP mice, splenic macrophages from pregnant ITP mice showed increased HIF-1α expression, higher glycolytic activity, enhanced phagocytic function, and more severe thrombocytopenia. Administration of tofacitinib not only suppressed HIF-1α expression but also effectively increased platelet counts. Consistent with these findings, similar results were also obtained in mice with sustained E2 exposure, confirming that E2 promoted macrophage metabolic and phagocytic reprogramming and that JAK inhibition counteracts its deleterious effects.
Conclusions: Our findings indicate that elevated E2 expression reprograms metabolism and enhances phagocytosis in macrophages via the ERα/HIF-1α axis, which is reversed by tofacitinib. This study provides novel insights into the pathogenesis of ITP during pregnancy and supports tofacitinib as a promising therapeutic approach.
Jie Chen: No relevant conflicts of interest to declare.